NextVivo

NextVivo is a biotechnology company focused on developing therapeutic organoid technology to create safer and more effective therapies. The company leverages immune competent human-derived models to test and generate treatments, primarily targeting cancer, infections, and autoimmune diseases. NextVivo operates in the preclinical drug discovery and development market, serving pharmaceutical companies and research institutions. The business model revolves around partnerships and collaborations, where it provides its proprietary organoid platform to aid in the development of targeted and cellular therapies. Revenue is generated through research collaborations, licensing agreements, and potential future product sales.

Keywords: therapeutic organoid, immune competent models, cancer therapy, infection treatment, autoimmune disease, drug discovery, preclinical development, targeted therapies, cellular therapies, biotechnology.